In a large, propensity-matched study, adult patients with type 2 diabetes who were newly prescribed a sodium-glucose cotransporter-2 (SGLT-2) inhibitor had a lower rate of incident gout than those newly prescribed a glucagon-like peptide-1 (GLP-1) receptor agonist.
14 Feb 2020
In the past six years, nearly three times as many cases of Fournier gangrene were reported in patients taking sodium-glucose cotransporter-2 (SGLT2) inhibitors as in the past 35 years in patients taking other antiglycemic agents.
10 May 2019
Expert panel recommends SGLT2 inhibitor or GLP-1 receptor agonist for patients with type 2 diabetes and CVD
The American College of Cardiology's new decision pathway also calls for repeated HbA1c screening and detailed clinician-patient risk discussions for patients with cardiovascular disease (CVD) who are diagnosed with type 2 diabetes.
14 Dec 2018
A retrospective cohort study in Taiwan found that antidepressant use was associated with a significantly reduced risk for death, and after adjustment, total mortality decreased as total cumulative antidepressant dose increased.
12 Jul 2019
Patients in a Chinese study received six automated text messages per week with educational and motivational information on glucose monitoring, blood pressure control, medication adherence, physical activity, and lifestyle.
13 Sep 2019
More care by nurse practitioners (NPs) and physician assistants (PAs) may be a way to expand primary care access while maintaining quality standards.
14 Dec 2018
The Endocrine Society's new clinical practice guideline recommends lifestyle therapy, then metformin, then second-line drugs (but not sulfonylureas and glinides) or insulin for diabetes patients ages 65 years and older, among other advice.
5 Apr 2019
The evidence-based guidance statement from ACP calls for personalized goals and an HbA1c target between 7% and 8% for most patients with type 2 diabetes.
9 Mar 2018
Lower glucose levels before hospital discharge associated with readmission, death in diabetes patients
Even near-normal glucose levels on the last day of hospitalization were associated with increased risk for readmission and postdischarge mortality, and these risks increased as patients' glucose levels decreased.
10 May 2019
Although canagliflozin has been linked to decreased bone mineral density, patients with type 2 diabetes who initiated the drug had similar risk of a first fracture as those who started a glucagon-like peptide-1 receptor agonist.
11 Jan 2019